A result of prospective biomarker trial on excision repair cross complementing group 1 (ERCC1) in advanced non-small-cell lung cancer: ERCC1 trial

Chemotherapies with platinum doublet have an important role in managing lung cancers in spite of progress on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) or anaplastic lymphoma kinase (ALK)-inhibitor. However, we cannot customize current cytotoxic chemotherapies to heighten an effect of treatment and prevent adverse drug reactions because there are no available biomarkers in practice. Development of biomarkers to predict a survival benefit for platinum-based chemotherapy is of importance in treatment for patients with lung cancer. Excision repair cross complementing group 1 (ERCC1) is one of the most promising
biomarker (1), which proteins play an essential role in nucleotide excision repair (2).